Clinical trials: Secondary Progressive Multiple Sclerosis (SPMS)
Secondary Progressive Multiple Sclerosis
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether MIS416 administered once weekly over 12 months is safe, tolerable, and improves a range of signs and symptoms associated with secondary progressive multiple sclerosis.
- Trial name
- NCT02228213
- Testing
- MIS416, Saline
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 93 people
- Sponsor
- Innate Immunotherapeutics
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors.
- Trial name
- POR-BetaPlus (NCT01235455)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Portugal
- Volunteers
- 10 people
- Sponsor
- Bayer
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Multiple Sclerosis
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with Multiple Sclerosis.
- Trial name
- STEM (NCT03983681)
- Testing
- Strategy-Based Training to Enhance Memory (STEM)
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kessler Foundation
Progressive Multiple Sclerosis
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
- Trial name
- MAXIMS (NCT05441488)
- Testing
- Masitinib (4.5)
- Where
- 37 sites in France, Greece and 6 more
- Volunteers
- 800 people
- Sponsor
- AB Science
Secondary Progressive Multiple Sclerosis
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in…
- Trial name
- NCT05826028
- Where
- 2 sites in Australia
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)
The goal of this clinical trial is to determine whether treatment with indapamide can slow the rate of progression in patients with progressive forms of multiple sclerosis (MS).
- Trial name
- INDAMS (NCT07765212)
- Testing
- Indapamide
- Volunteers
- 75 people
- Sponsor
- Eva M.M. Strijbis
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Multiple Sclerosis, Secondary Progressive
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive…
- Trial name
- INSPIRE (NCT02430532)
- Testing
- dimethyl fumarate
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- Biogen
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer